Abstract
摘要
相似文献
1
Rosuvastatin receives FDA approval.
Cardiovasc J S Afr. 2003 Sep-Oct;14(5):286.
2
Two more drugs for dyslipidemia.
Am J Cardiol. 2004 Mar 15;93(6):809-11. doi: 10.1016/j.amjcard.2004.01.022.
3
The statin wars.
Lancet. 2003 Nov 1;362(9394):1498. doi: 10.1016/S0140-6736(03)14698-3.
4
Statins: how far have we come? A review of rosuvastatin.
Int J Clin Pract Suppl. 2003 Oct(137):15-25.
5
Was the FDA misled by JUPITER?
J Am Osteopath Assoc. 2010 Aug;110(8):424-5.
6
FDA approves a statin therapy for some: certain, asymptomatic individuals targeted.
JAMA. 2010 Apr 7;303(13):1242-3. doi: 10.1001/jama.2010.342.
7
Rosuvastatin: winner in the statin wars, patients' health notwithstanding.
BMJ. 2015 Mar 17;350:h1388. doi: 10.1136/bmj.h1388.
8
Rosuvastatin as a novel treatment of non-alcoholic fatty liver disease in hyperlipidemic patients.
Atherosclerosis. 2006 Jan;184(1):233-4. doi: 10.1016/j.atherosclerosis.2005.08.021. Epub 2005 Oct 5.
9
The stain wars.
Lancet. 2003 Nov 29;362(9398):1855-6; discussion 1856. doi: 10.1016/s0140-6736(03)14934-3.
10
[JUPITER study (2). For now no reason to give statins to more people].
Ned Tijdschr Geneeskd. 2009 Feb 7;153(6):218-9.
Zotero 插件